BioNexus Gene Lab Income Statement (2018-2026) | BGLC

Income Statement Mar2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
3.09M3.58M3.25M3.03M2.49M2.58M2.84M2.38M2.57M2.55M2.27M2.38M1.97M2.63M2.52M2.14M2.26M2.54M0.48M0.02M
Cost of Revenue (Quarter)
2.62M2.87M2.77M2.67M2.22M2.28M2.50M2.01M2.23M2.20M2.01M2.02M1.69M2.30M2.21M1.79M1.89M2.17M0.49M0.02M
Gross Profit (Quarter)
0.47M0.71M0.48M0.36M0.26M0.30M0.34M0.37M0.34M0.35M0.27M0.37M0.29M0.33M0.31M0.34M0.37M0.38M-0.00M-790.00
Operating items
Research & Development (Quarter)
0.01M0.14M0.01M-1.49M0.01M0.61M0.01M1.70M0.05M
Selling, General & Administrative (Quarter)
0.38M0.38M0.18M0.37M0.45M0.42M0.49M0.54M0.81M3.08M-1.98M0.32M0.56M0.79M0.17M0.39M0.52M0.45M0.18M0.33M
Restructuring Costs (Quarter)
-0.26M0.07M1.16M0.37M0.45M0.42M0.49M0.54M0.81M3.08M-1.98M0.32M0.56M0.79M0.17M0.39M0.52M0.45M0.18M
Other Operating Expenses (Quarter)
-1.29M-0.49M0.53M2.56M0.26M-0.45M0.28M-1.01M0.22M
Operating Expenses (Quarter)
0.12M0.46M1.34M0.74M0.91M0.84M0.98M1.07M1.61M6.16M-3.97M-0.65M0.76M2.13M1.40M1.05M1.19M1.19M1.05M0.60M
Operating Income (Quarter)
0.14M0.37M0.20M0.03M-0.14M-0.07M-0.12M-0.05M-0.27M-2.53M0.26M-0.08M0.26M-1.34M-0.42M-0.62M-0.61M-0.70M-1.03M-0.54M
EBIT (Quarter)
0.14M0.37M0.20M0.03M-0.14M-0.07M-0.12M-0.05M-0.27M-2.53M0.26M-0.08M0.26M-1.34M-0.42M-0.62M-0.61M-0.70M-1.03M-0.54M
Non-operating items
Non Operating Investment Income (Quarter)
0.08M0.09M0.07M-0.17M0.00M0.02M-0.03M
Interest & Investment Income (Quarter)
0.03M0.05M0.04M0.03M0.02M0.03M0.02M0.01M0.02M
Other Non Operating Income (Quarter)
-0.01M-0.06M0.04M-0.07M0.20M0.73M0.47M0.67M0.09M0.21M0.11M0.02M0.06M
Net income details
EBT (Quarter)
0.14M0.37M0.20M0.03M-0.14M-0.07M-0.13M-0.05M-0.28M-2.53M0.25M-0.08M0.25M-1.34M-0.42M-0.62M-0.62M-0.71M-1.04M-0.54M
Tax Provisions (Quarter)
0.11M0.08M0.08M0.01M-0.00M0.01M-0.19M0.02M0.02M0.08M-0.10M-0.02M0.06M0.00M-0.09M
Profit After Tax (Quarter)
0.03M0.24M0.13M0.02M-0.14M-0.08M0.55M-0.07M-0.26M-2.61M0.31M-0.10M0.20M-0.30M-1.07M-0.55M-0.62M-0.71M-1.04M-0.54M
Income from Continuing Operations (Quarter)
0.03M0.30M0.12M0.02M-0.14M-0.08M0.07M-0.07M-0.29M-2.61M0.35M-0.06M0.20M-1.35M-0.33M-0.62M-0.62M-0.71M-1.04M-0.54M
Consolidated Net Income (Quarter)
0.03M0.30M0.12M0.02M-0.14M-0.08M0.07M-0.07M-0.29M-2.61M0.35M-0.06M0.20M-1.35M-0.33M-0.62M-0.62M-0.71M-1.04M-0.54M
Income towards Parent Company (Quarter)
0.03M0.30M0.12M0.02M-0.14M-0.08M0.07M-0.07M-0.29M-2.61M0.35M-0.06M0.20M-1.35M-0.33M-0.62M-0.62M-0.71M-1.04M-0.54M
Net Income towards Common Stockholders (Quarter)
0.03M0.30M0.12M0.02M-0.14M-0.08M0.07M-0.07M-0.29M-2.61M0.35M-0.10M0.20M-1.35M-0.35M-0.62M-0.62M-0.71M-1.04M-0.54M
Additional items
EPS (Basic) (Quarter)
0.020.210.080.01-0.10-0.050.05-0.05-0.02-1.560.22-0.060.11-0.75-0.20-0.35-0.35-0.40-0.56-0.29
EPS (Diluted) (Quarter)
0.02-0.010.11-0.75-0.02-0.03-0.34-0.39-0.58-0.22
Shares Outstanding (Quarter)
1.43M1.43M1.43M1.43M1.43M1.45M1.44M1.45M17.37M1.68M1.59M1.77M1.77M1.80M1.78M1.78M1.78M1.78M1.86M1.86M
Shares Outstanding (Diluted) (Quarter)
15.88M17.67M1.77M1.80M17.82M17.97M1.80M1.80M1.80M2.42M
Shares Outstanding (Entity) (Quarter)
1.43M1.43M1.43M1.43M1.45M1.45M1.45M1.45M1.78M1.77M1.77M1.77M1.80M1.78M1.80M1.80M1.86M2.42M
EBITDA (Quarter)
0.14M0.37M0.20M0.03M-0.14M-0.07M-0.12M-0.05M-0.27M-2.53M0.26M-0.08M0.26M-1.34M-0.42M-0.62M-0.61M-0.70M-1.03M-0.54M
Interest Expenses (Quarter)
0.00M-0.00M0.02M0.01M0.00M-0.00M-0.00M0.00M-0.00M0.00M0.00M0.01M0.00M0.01M0.01M10.03M0.03M0.05M-0.04M12.16M
Tax Rate (Quarter)
79.30%20.29%41.15%45.59%1.16%-15.03%151.62%-30.13%-5.81%-3.02%-38.63%23.98%21.82%-0.12%22.04%